Eisai's efforts to deliver its FDA-approved Alzheimer's drug to sufferers in Europe have suffered a setback. A committee of the European Medicines Company has advisable in opposition to granting advertising authorization for the product Leqembi, saying the advantages of the remedy don’t outweigh its dangers. The opinion issued Thursday by the EMA's Committee for Medicinal Merchandise for Human Use (CHMP) […]